Immunosuppression in inflammatory cardiomyopathy and parvovirus B19 persistence
Parvovirus B19 (B19V) infection is acquired in childhood and persists lifelong in approximately 70% of healthy adults and may belong Figure 1 Changes in left ventricular ejection fraction (LVEF), grade of inflammation and parvovirus B19 (B19V) copy number following 6 months of immunosuppressive treatment. LVEF change between baseline and after 6 months of treatment with prednisolone (1 mg/kg once daily tapered by 10 mg biweekly) and 100 mg azathioprine in addition to standard heart failure medication was not different between B19V-positive (A) and -negative (B) patients (LVEF 9.4 ± 14.0%, n = 51 vs. LVEF 9.7 ± 11.8%, n = 17, P = 0.9023). Transcriptionally active patients (determined as copy numbers/μg mRNA) are shown in red. The grade of inflammation (defined as grade I ≥ 14 leucocytes/mm 2 including up to 4 monocytes/mm 2 with the presence of CD3-positive T-lymphocytes ≥ 7 cells/mm 2 and grade II if > 2X grade I counts) was significantly reduced in both B19V-positive (C) and -negative (D) patients by a mean of 0.86 ± 0.63 (n = 51) and 0.82 ± 0.63 (n = 17) grade points, respectively. (E) B19V viral loads after treatment (determined as copy numbers/μg DNA) were not significantly varied from baseline; lines representing patients who were B19V-negative at baseline are shown in red; 53 patients showed detectable B19V DNA before or after treatment. Haemodynamic improvement was found in both B19V-positive and -negative patients with biopsy-proven myocardial inflammation, and analysed subgroups, justifying anti-inflammatory treatment. In the univariate analysis, left ventricular improvement was independent of the presence or absence of virus, the virus load or the presence or magnitude of the mRNA copy numbers. *P < 0.05, **P < 0.01, ***P < 0.001. All patients have signed an informed consent according to the local ethics committee (application no. EA2/140/16). Paired t-test was used to compare the results at the two time points (before vs. after treatment). EF, ejection fraction.
to a cardiac bioportfolio without clinical significance. 1 However, B19V DNA is also found in the majority of chronic inflammatory cardiomyopathy patients with low copy numbers, questioning whether this finding contributes to the disease and influences treatment implications. [2] [3] [4] Current European Society of Cardiology and American Heart Association recommendations support an anti-inflammatory treatment regime in inflammatory cardiomyopathy patients when active cardiac infection is excluded. 5 Whether this precaution holds true for patients with B19V persistence, which does not principally represents an active infection, is under discussion. 4 To gain insights into immunosuppressive treatment effects of B19V-negative and -positive patients with endomyocardial biopsy (EMB)-proven inflammatory cardiomyopathy, we compared the changes in systolic left ventricular ejection fraction (LVEF, %), B19V viral genome copy numbers (B19V 
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(65%), mean age 45.1 ± 14.8 years, 9 (11.6%) with > 500 DNA copies/μg DNA] and 17 virus-negative patients with inflammatory cardiomyopathy [12 men (70.6%), mean age 45.6 ± 13.9 years] during a 6-month course with prednisolone and azathioprine regimen in addition to standard heart failure medication in a single-centre observational investigation. Patient characteristics before and after treatment are displayed in the online supplementary Table S1 . Six months after treatment, inflammatory infiltrates had resolved in 12 (70.5%) virus-negative (P < 0.0001) and 34 (66%) B19V DNApositive patients (P < 0.0001) ( Figure 1C and  1D) . B19V copy number did not significantly change ( Figure 1E) . LVEF of both groups improved similarly upon treatment ( Figure  1A and 1B) . This result was also seen in 8 patients who showed in addition a transcriptional activity at baseline (viral mRNA VP1/VP2 3 ) ( Figure 1A) . Neither viral copy number nor transcriptional activity correlated with the LVEF response. EMB material from 22 patients allowed extra experimental insights demonstrating the down-regulation of the innate immune mediators nucleotidebinding oligomerization domain 2 (NOD2), caspase 1 and interleukin-1 (online supplementary Figure S1 ) following the course of treatment, suggesting that the treatment reduced inflammatory, apoptotic, and pyroptotic signalling, independent of B19V persistence. An extended observation (mean 13 months after treatment) of 35 available patients showed a stable LVEF improvement in both groups.
We conclude that patients with inflammatory cardiomyopathy and B19V persistence without signs of systemic active infection may gain a similar long lasting and safe benefit from immunosuppressive treatment, as do viral negative individuals. These results need further verification in a randomized controlled trial.
Supplementary Information
Additional supporting information may be found online in the Supporting Information section at the end of the article. Figure S1 . Cardiac gene expression changes following 6 months of immunosuppressive treatment. (A) Heat map showing the change in the gene expression profile between baseline and after 6 months of treatment with prednisolone (1 mg/kg once daily, tapered by 10 mg biweekly) and 100 mg azathioprine on top of standard heart failure medications in endomyocardial biopsy samples from 22 B19V+ patients. Gene expression was measured via quantitative real-time PCR, with 18S ribosomal subunit used as housekeeping gene. The left panel demonstrates the patients with up-regulation in the expression of most genes. Red colour denotes an increased expression, whereas blue colour denotes a reduced expression. The heat blot was created via R version 3.5.2. The gene expression levels of the innate immunity inflammatory protein NOD2 (B), the pro-apototic/propyroptotic enzyme caspase 1 (C), and the pro-inflammatory cytokine interleukin-1 (D) were reduced by 2.4-fold, 1.7-fold and 2.6-fold following the treatment course (n = 18), respectively. *P < 0.05. Paired t-test was used to compare the results at the two time points (before vs. after treatment). Table S1 . Baseline and post-treatment characteristics of the patients.
